摘要
近10年,耐多药结核病全球形势严峻,2009年的监测结果显示:初治肺结核患者耐多药率为0.0%～28.3%,复治肺结核患者耐多药率为0.0%～61.6%。我国是全球耐多药结核病高负担国家之一,耐多药和超级耐药结核病患者数均列世界首位。对此,最重要的是对其加强监测和进行准确诊断,强调早期合理用药和个体化的全程直接督导化疗,按照WHO的建议来指导治疗。
Multidrug-resistant tuberculosis （MDR-TB） has been a major global public health threat since the last decade. According to the results of the survey in 2009, primary MDR-TB was 0.0%-28.3% and acquired MDR-TB was 0.0%-61.6%. China is one of the global high-burden MDR-TB countries and its cases of both MDR-TB and extensively drug-resistant TB account for the largest proportion of such cases all over the world. So it has been suggested that close monitoring and accurate diagnosis of MDR-TB, rational use of drugs at an early stage and individualized directly-observed treatment strategy should be emphasized and enhanced, and the treatment should be guided by WHO＇s suggestions.
出处
《传染病信息》
2011年第2期117-120,共4页
Infectious Disease Information
基金
国家"十一五"科技重大专项(2008ZX10005-013)
关键词
结核
肺
抗药性
多药
结核分枝杆菌
tuberculosis, pulmonary
drug resistance, muhiple
Mycobacterium tuberculosis
